+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Eculizumab Market - Global Forecast 2026-2032- Product Image
Eculizumab Market - Global Forecast 2026-2032- Product Image
New

Eculizumab Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 194 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6118475
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The eculizumab market is evolving rapidly, shaped by ongoing clinical advances, shifting care models, and dynamic stakeholder requirements. Senior decision-makers face a landscape in which therapeutic innovation, operational complexity, and resilient access strategies all converge to define future growth.

Market Snapshot: Eculizumab Market Size and Growth

The Eculizumab Market grew from USD 4.35 billion in 2025 to USD 4.53 billion in 2026 and is projected to expand at a CAGR of 5.19%, reaching USD 6.21 billion by 2032. This trajectory reflects increasing clinical adoption in rare conditions, evolving payer frameworks, and heightened focus on supply reliability.

Scope & Segmentation of the Eculizumab Market

This report offers in-depth coverage across multiple segments, reflecting the full product and patient ecosystem of eculizumab therapy:

  • Indications: Atypical Hemolytic Uremic Syndrome (First Line, Second Line), Generalized Myasthenia Gravis (Non-Refractory, Refractory), Neuromyelitis Optica Spectrum Disorder (Non-Refractory, Refractory), Paroxysmal Nocturnal Hemoglobinuria (First Line, Second Line)
  • Distribution Channels: Hospital Pharmacy (Secondary Hospitals, Tertiary Hospitals), Retail Pharmacy (Chain Pharmacy, Independent Pharmacy)
  • End Users: Hospitals (Secondary Hospitals, Tertiary Hospitals), Specialty Clinics (Hematology Clinics, Neurology Clinics)
  • Patient Age Groups: Adult (19-65, Over 65), Pediatric (Adolescent, Neonatal)
  • Regions: Americas, EMEA, Asia-Pacific – each with unique regulatory, reimbursement, and infrastructure considerations
  • Technologies: Monoclonal antibody production platforms, infusion and, where available, investigational subcutaneous delivery systems

Key Takeaways: Eculizumab Market Trends and Opportunities

  • Therapy adoption is expanding beyond initial orphan indications to broader immunohematologic and neuroimmunologic disorders, requiring refined patient identification and ongoing safety monitoring.
  • Care models are increasingly multidisciplinary, integrating vaccination strategies, remote monitoring, and coordinated support services to ensure therapy adherence and risk management.
  • Innovation in delivery technology, such as extended-interval and investigational subcutaneous approaches, has begun to reduce traditional infusion burdens and may enable more flexible treatment settings.
  • Payer and provider alignment on value-based frameworks is influencing reimbursement and encouraging outcomes-based contracts that link cost to patient benefit.
  • Regional market entry and long-term access are shaped by divergent regulatory landscapes, necessitating agile partnership strategies and local adaptation in product distribution and patient education models.
  • Competitive intensity is increasing as new complement inhibitors and alternative biologics enter development pipelines, prompting lifecycle management investments and collaboration to maintain therapeutic relevance.

Tariff Impact on Biologics Supply Chains, Manufacturing, and Negotiation

Tariff measures introduced in 2025 have added complexity for eculizumab supply and economics. These changes drive increased emphasis on local and regional manufacturing to buffer against cost fluctuations and cross-border logistics risks. Manufacturers are optimizing supplier diversification and contract strategies, while payers are intensifying value-based procurement and exploring alternative sourcing to protect patient care continuity.

Direct cost pressures from tariffs have led stakeholders to renegotiate multi-year contracts and seek regulatory clarity. The industry’s response centers on ensuring supply chain flexibility, engaging policymakers for exemptions, and reinforcing clinical continuity amidst evolving macroeconomic challenges.

Methodology & Data Sources

Primary research for this report involved structured interviews with hematologists, neurologists, hospital pharmacy leaders, and payer stakeholders. Secondary data synthesis incorporated peer-reviewed publications, regulatory filings, clinical guidelines, and validated product information. Analytical rigor was maintained through triangulation of real-world evidence and expert validation.

Why This Report Matters

  • Enables decision-makers to optimize investment and operational strategy in a complex, controlled therapeutic category.
  • Supports effective product positioning by clarifying segmentation, technology, and regional dynamics across the eculizumab market.
  • Informs procurement and market access strategy by detailing tariff effects, manufacturing resilience, and regulatory engagement needs.

Conclusion

This report delivers clear, actionable intelligence on the evolving eculizumab market. Strategic integration of clinical, operational, and regulatory insights empowers stakeholders to respond to changing demands in rare disease therapeutics and secure patient access with confidence.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Impact of biosimilar entry on global pricing and access dynamics for eculizumab
5.2. Analysis of long-term real world safety and treatment discontinuation rates in PNH patients on eculizumab therapy
5.3. Emerging clinical trial data supporting eculizumab approval in neuromyelitis optica spectrum disorder patients
5.4. Competitive landscape shift driven by development of next generation complement inhibitors challenging eculizumab market dominance
5.5. Health economic assessments highlighting cost effectiveness of eculizumab compared to emerging complement targeting therapies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Eculizumab Market, by Indication
8.1. Introduction
8.2. Atypical Hemolytic Uremic Syndrome
8.2.1. First Line
8.2.2. Second Line
8.3. Generalized Myasthenia Gravis
8.3.1. Non-Refractory
8.3.2. Refractory
8.4. Neuromyelitis Optica Spectrum Disorder
8.4.1. Non-Refractory
8.4.2. Refractory
8.5. Paroxysmal Nocturnal Hemoglobinuria
8.5.1. First Line
8.5.2. Second Line
9. Eculizumab Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.2.1. Secondary Hospitals
9.2.2. Tertiary Hospitals
9.3. Retail Pharmacy
9.3.1. Chain Pharmacy
9.3.2. Independent Pharmacy
10. Eculizumab Market, by End User
10.1. Introduction
10.2. Hospitals
10.2.1. Secondary Hospitals
10.2.2. Tertiary Hospitals
10.3. Specialty Clinics
10.3.1. Hematology Clinics
10.3.2. Neurology Clinics
11. Eculizumab Market, by Patient Age Group
11.1. Introduction
11.2. Adult
11.2.1. 19-65
11.2.2. Over 65
11.3. Pediatric
11.3.1. Adolescent
11.3.2. Neonatal
12. Americas Eculizumab Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Eculizumab Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Eculizumab Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Alexion Pharmaceuticals, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ECULIZUMAB MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ECULIZUMAB MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ECULIZUMAB MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ECULIZUMAB MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ECULIZUMAB MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ECULIZUMAB MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ECULIZUMAB MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ECULIZUMAB MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ECULIZUMAB MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS ECULIZUMAB MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ECULIZUMAB MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES ECULIZUMAB MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ECULIZUMAB MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. ECULIZUMAB MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. ECULIZUMAB MARKET: RESEARCHAI
FIGURE 24. ECULIZUMAB MARKET: RESEARCHSTATISTICS
FIGURE 25. ECULIZUMAB MARKET: RESEARCHCONTACTS
FIGURE 26. ECULIZUMAB MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ECULIZUMAB MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ECULIZUMAB MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ECULIZUMAB MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ECULIZUMAB MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ECULIZUMAB MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ECULIZUMAB MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ECULIZUMAB MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ECULIZUMAB MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ECULIZUMAB MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ECULIZUMAB MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ECULIZUMAB MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ECULIZUMAB MARKET SIZE, BY NON-REFRACTORY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ECULIZUMAB MARKET SIZE, BY NON-REFRACTORY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ECULIZUMAB MARKET SIZE, BY REFRACTORY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ECULIZUMAB MARKET SIZE, BY REFRACTORY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ECULIZUMAB MARKET SIZE, BY NON-REFRACTORY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ECULIZUMAB MARKET SIZE, BY NON-REFRACTORY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ECULIZUMAB MARKET SIZE, BY REFRACTORY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ECULIZUMAB MARKET SIZE, BY REFRACTORY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ECULIZUMAB MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ECULIZUMAB MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ECULIZUMAB MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ECULIZUMAB MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ECULIZUMAB MARKET SIZE, BY SECONDARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ECULIZUMAB MARKET SIZE, BY SECONDARY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ECULIZUMAB MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ECULIZUMAB MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ECULIZUMAB MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ECULIZUMAB MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ECULIZUMAB MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ECULIZUMAB MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ECULIZUMAB MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ECULIZUMAB MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ECULIZUMAB MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ECULIZUMAB MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ECULIZUMAB MARKET SIZE, BY SECONDARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ECULIZUMAB MARKET SIZE, BY SECONDARY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ECULIZUMAB MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ECULIZUMAB MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ECULIZUMAB MARKET SIZE, BY HEMATOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ECULIZUMAB MARKET SIZE, BY HEMATOLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ECULIZUMAB MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ECULIZUMAB MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ECULIZUMAB MARKET SIZE, BY 19-65, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ECULIZUMAB MARKET SIZE, BY 19-65, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ECULIZUMAB MARKET SIZE, BY OVER 65, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ECULIZUMAB MARKET SIZE, BY OVER 65, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ECULIZUMAB MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ECULIZUMAB MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ECULIZUMAB MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ECULIZUMAB MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ECULIZUMAB MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ECULIZUMAB MARKET SIZE, BY ADOLESCENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ECULIZUMAB MARKET SIZE, BY NEONATAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ECULIZUMAB MARKET SIZE, BY NEONATAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ECULIZUMAB MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ECULIZUMAB MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS ECULIZUMAB MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS ECULIZUMAB MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS ECULIZUMAB MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS ECULIZUMAB MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS ECULIZUMAB MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS ECULIZUMAB MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS ECULIZUMAB MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS ECULIZUMAB MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES ECULIZUMAB MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES ECULIZUMAB MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES ECULIZUMAB MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES ECULIZUMAB MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES ECULIZUMAB MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES ECULIZUMAB MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES ECULIZUMAB MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES ECULIZUMAB MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES ECULIZUMAB MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 157. CANADA ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 158. CANADA ECULIZUMAB MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 159. CANADA ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 160. CANADA ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 161. CANADA ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2024 (USD MILLION)
TABLE 162. CANADA ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2025-2030 (USD MILLION)
TABLE 163. CANADA ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2024 (USD MILLION)
TABLE 164. CANADA ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2025-2030 (USD MILLION)
TABLE 165. CANADA ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 166. CANADA ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 167. CANADA ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. CANADA ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. CANADA ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 170. CANADA ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 171. CANADA ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 172. CANADA ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 173. CANADA ECULIZUMAB MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. CANADA ECULIZUMAB MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. CANADA ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 176. CANADA ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 177. CANADA ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 178. CANADA ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 179. CANADA ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 180. CANADA ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 181. CANADA ECULIZUMAB MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 182. CANADA ECULIZUMAB MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 183. CANADA ECULIZUMAB MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 184. CANADA ECULIZUMAB MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 185. MEXICO ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 186. MEXICO ECULIZUMAB MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 187. MEXICO ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 188. MEXICO ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 189. MEXICO ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2024 (USD MILLION)
TABLE 190. MEXICO ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2025-2030 (USD MILLION)
TABLE 191. MEXICO ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2024 (USD MILLION)
TABLE 192. MEXICO ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2025-2030 (USD MILLION)
TABLE 193. MEXICO ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 194. MEXICO ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 195. MEXICO ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. MEXICO ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. MEXICO ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 198. MEXICO ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 199. MEXICO ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 200. MEXICO ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 201. MEXICO ECULIZUMAB MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. MEXICO ECULIZUMAB MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. MEXICO ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 204. MEXICO ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 205. MEXICO ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 206. MEXICO ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 207. MEXICO ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 208. MEXICO ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 209. MEXICO ECULIZUMAB MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 210. MEXICO ECULIZUMAB MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 211. MEXICO ECULIZUMAB MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 212. MEXICO ECULIZUMAB MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL ECULIZUMAB MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL ECULIZUMAB MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL ECULIZUMAB MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 237. BRAZIL ECULIZUMAB MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 238. BRAZIL ECULIZUMAB MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 239. BRAZIL ECULIZUMAB MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 240. BRAZIL ECULIZUMAB MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA ECULIZUMAB MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA ECULIZUMAB MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA ECULIZUMAB MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 261. ARGENTINA ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 262. ARGENTINA ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 263. ARGENTINA ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 264. ARGENTINA ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 265. ARGENTINA ECULIZUMAB MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 266. ARGENTINA ECULIZUMAB MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 267. ARGENTINA ECULIZUMAB MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 268. ARGENTINA ECULIZUMAB MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 297. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 298. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2025-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2024 (USD MILLION)
TABLE 306. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2025-2030 (USD MILLION)
TABLE 307. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 308. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 309. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 310. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 311. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 312. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 313. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 314. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 315. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 316. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 317. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 318. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 319. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 320. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 321. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 322. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 323. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 324. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 325. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 326. UNITED KINGDOM ECULIZUMAB MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 327. GERMANY ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 328. GERMANY ECULIZUMAB MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 329. GERMANY ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 330. GERMANY ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 331. GERMANY ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2024 (USD MILLION)
TABLE 332. GERMANY ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2025-2030 (USD MILLION)
TABLE 333. GERMANY ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2024 (USD MILLION)
TABLE 334. GERMANY ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2025-2030 (USD MILLION)
TABLE 335. GERMANY ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 336. GERMANY ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 337. GERMANY ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 338. GERMANY ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 339. GERMANY ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 340. GERMANY ECULIZUMAB MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 341. GERMANY ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 342. GERMANY ECULIZUMAB MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 343. GERMANY ECULIZUMAB MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 344. GERMANY ECULIZUMAB MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 345. GERMANY ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 346. GERMANY ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 347. GERMANY ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 348. GERMANY ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 349. GERMANY ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MIL

Companies Mentioned

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Catalyst Biosciences, Inc.
  • Celltrion Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Samsung Bioepis Co., Ltd.
  • Sanofi SA
  • Swedish Orphan Biovitrum AB
  • UCB S.A.

Table Information

Report AttributeDetails
No. of Pages194
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 4.53 Billion
Forecasted Market Value ( USD ) by 2032 $ 6.21 Billion
Compound Annual Growth Rate5.1%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Complement Inhibitors Market - Global Forecast 2026-2032 - Product Image

Complement Inhibitors Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
C5 Complement Inhibitors Market Report 2025 - Product Image

C5 Complement Inhibitors Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria Drugs Market - Global Forecast 2025-2030 - Product Image

Paroxysmal Nocturnal Hemoglobinuria Drugs Market - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Atypical Hemolytic Uremic Syndrome Treatment Market Report 2025 - Product Image

Atypical Hemolytic Uremic Syndrome Treatment Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Atypical Hemolytic Uremic Syndrome (aHUS) - Pipeline Insight, 2025 - Product Image

Atypical Hemolytic Uremic Syndrome (aHUS) - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From

About the Eculizumab Market

Eculizumab is a monoclonal antibody used to treat hematological diseases, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). It is a recombinant humanized IgG4 kappa monoclonal antibody that binds to and inhibits the activity of complement component 5 (C5). By blocking C5, eculizumab prevents the formation of the membrane attack complex (MAC), which is responsible for the destruction of red blood cells in PNH and aHUS. Eculizumab is the only approved therapy for PNH and aHUS, and is the only drug that can stop the progression of these diseases. It is administered intravenously, and is typically given once every two weeks. Eculizumab is also being studied for its potential use in other hematological diseases, such as myasthenia gravis and neuromyelitis optica. Companies in the eculizumab market include Alexion Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., and GlaxoSmithKline plc. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.